Motley Fool Asset Management’s 10x Genomics TXG Stock Holding History
Bought
Maintained
Sold
Other funds holding TXG
AIM
1WCM
FCMI
Motley Fool Asset Management's TXG Position: Q1 2022 in Review
Motley Fool Asset Management sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 52 shares — an estimated $8K sold.
Motley Fool Asset Management first reported a position in TXG in Q4 2021 and held it in 1 quarter. The position peaked at $8K in Q4 2021. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.
- Motley Fool Asset Management reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
- Motley Fool Asset Management sold 52 10x Genomics shares in Q1 2022, an estimated $8K.
- Motley Fool Asset Management first reported a position in 10x Genomics in Q4 2021 and held it in 1 quarter.
- Motley Fool Asset Management's 10x Genomics position peaked at $8K in Q4 2021.
- 314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.
Based on Motley Fool Asset Management's 13F filing for Q1 2022, filed 4 May 2022.